Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSC in SARS-CoV-2 Infected Subjects
NCT04573322Phase 2Completed
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trans sodium crocetinate in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Diffusion Pharmaceuticals Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 70 days and Time to Recovery Through Day 28. Started Sep 2020; status: completed.
02
Drugs
trans sodium crocetinate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04573322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573322.